Predicting resectability of primary tumor and mesenteric lymph-node masses in patients with small-intestine neuroendocrine tumors
- PMID: 35224681
- DOI: 10.1007/s13304-022-01251-3
Predicting resectability of primary tumor and mesenteric lymph-node masses in patients with small-intestine neuroendocrine tumors
Abstract
Background: Vascular infiltration may jeopardize resection of the primary tumor and mesenteric metastatic masses in small-intestine neuroendocrine tumors (SI-NETs). However, other factors may play a role in predicting resectability.
Methods: After computed tomography (CT) scan, three radiological parameters were considered: (1) degree of superior mesenteric artery involvement (SMA) according to a previous classification (2) degree of superior mesenteric venous involvement (SMV) as either absent, peripheral or proximal (3) presence or not of mesenteric fibrosis retraction (MF). Pre-surgical parameters were matched to surgical outcome.
Results: Forty-nine consecutive patients were submitted to laparotomy. Of them, 37 had complete primary tumor and mesenteric masses resection. SMA (p = 0.001), SMV (p = 0.008), metastasis site (p = 0.001) and MF (p < 0.001) were all significantly associated with the likelihood to receive resection at univariate analysis. All the five patients with infiltration of SMV proximal to middle colic vein were unresectable. At multivariable analysis excluding SMA stage, the absence of MF (HR 13.1, I.C. 1.44-119; p = 0.002) was the only factor associated with the likelihood to receive primary tumor and mesentery radical surgery.
Conclusions: SMA stage 3-up and/or signs of MF, as well as infiltration of SMV proximal to middle colic vein at CT scan are predictive of operative failure in patients with SI-NETs. The assessment of such factors should be always considered in the decision-making process of such patients especially in those with asymptomatic disease with synchronous unresectable liver metastases.
Keywords: Liver metastases; Liver resection; Primary tumor resection; Small intestine neuroendocrine tumors.
© 2022. Italian Society of Surgery (SIC).
References
-
- Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y et al (2017) Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 3(10):1335–1342 - DOI
-
- Keck KJ, Maxwell JE, Utria AF, Bellizzi AM, Dillon JS, O’Dorisio TM et al (2018) The distal predilection of small bowel neuroendocrine tumors. Ann Surg Oncol 25(11):3207–3213 - DOI
-
- Niederle B, Pape U-F, Costa F et al (2016) ENETS Consensus Guidelines ENETS Consensus Guidelines update for neuroendocrine neoplasms of the Jejunum and Ileum. Neuroendocrinology 103:125–138 - DOI
-
- Walsh JC, Schaeffer DF, Kirsch R et al (2016) Ileal “carcinoid” tumors—small size belies deadly intent: high rate of nodal metastasis in tumors ≤1 cm in size. Hum Pathol 56:123–127 - DOI
-
- Åkerström G, Hellman P, Hessman O (2005) Midgut carcinoid tumours: surgical treatment and prognosis. Best Pract Res Clin Gastroenterol 19:717–728 - DOI
MeSH terms
LinkOut - more resources
Full Text Sources